Jensen-Pergakes K, Tatlock J, Maegley KA, McAlpine IJ, et al. SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance. Mol Cancer Ther 2022;21:3-15.
PMID: 34737197